29.09.2015 • News

Sanofi and Lilly Settle Lantus Patent Row

France’s Sanofi and US drugmaker Eli Lilly have resolved their patent dispute over insulin drugs.

The settlement announced this week ends a US lawsuit brought by the French producer of Lantus SoloSTAR (insulin glargine) in response to its US rival’s pursuit of regulatory approval for a competitive product. The two companies also agreed to discontinue similar disputes worldwide.

As part of the agreement, Lilly will pay royalties to Sanofi in exchange for a license to certain Sanofi patents and will not sell its insulin glargine product on the US market before Dec.15, 2016. The agreement does not extend to Lantus (vial), Toujeo or combination products.

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

Top-Feature

most read